Gentris Announces Promotion and Strategic New Hire
Scott Clark promoted to Vice President of Research and Development; Heath Knight joins as Vice President of Business Development
Research Triangle Park, NC, December 15, 2005 --(PR.com)-- Gentris Corporation, a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, announced today that Scott Clark, Ph.D., has been promoted to Vice President of Research and Development from the position of Executive Director of Scientific Affairs. Gentris has also recruited accomplished scientist Heath Knight, Ph.D., as Vice President of Business Development.
A seasoned expert with over fifteen years experience in pharmacogenomics, Clark will be responsible for Gentris’ scientific strategy and will manage the Clinical Genetics Research and Development Division. “As Vice President of Research and Development, Scott will champion the development of the highest quality clinical pharmacogenomics testing services, so that our company may continue to provide customers with a greater array of solutions,” said Michael Murphy, President and CEO of Gentris.
Heath Knight, newly appointed Vice President of Business Development, has over thirteen years experience and has held senior management positions at prominent contract research organizations, including Lark Technologies, Commonwealth Biotechnologies, and RTI International. Knight received her doctorate in Human Genetics from the Medical College of Virginia and conducted post-doctoral training at Baylor College of Medicine and the Mayo Clinic. “By combining a solid scientific background with a proven track record for expanding profitable lines and exceeding sales targets, Heath brings tremendous value and skills to the Vice President of Business Development position,” commented Murphy.
###
About Gentris Corporation
Gentris Corporation is a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions. As pioneers in the field of pharmacogenomics, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market sooner. Gentris is developing diagnostic test kits and validated reference controls that will bring the promise of personalized medicine to physicians and patients, which will enhance patient management, improve patients' response to therapy and revolutionize medicine through pharmacogenomics. For additional information, please visit http://www.gentris.com.
A seasoned expert with over fifteen years experience in pharmacogenomics, Clark will be responsible for Gentris’ scientific strategy and will manage the Clinical Genetics Research and Development Division. “As Vice President of Research and Development, Scott will champion the development of the highest quality clinical pharmacogenomics testing services, so that our company may continue to provide customers with a greater array of solutions,” said Michael Murphy, President and CEO of Gentris.
Heath Knight, newly appointed Vice President of Business Development, has over thirteen years experience and has held senior management positions at prominent contract research organizations, including Lark Technologies, Commonwealth Biotechnologies, and RTI International. Knight received her doctorate in Human Genetics from the Medical College of Virginia and conducted post-doctoral training at Baylor College of Medicine and the Mayo Clinic. “By combining a solid scientific background with a proven track record for expanding profitable lines and exceeding sales targets, Heath brings tremendous value and skills to the Vice President of Business Development position,” commented Murphy.
###
About Gentris Corporation
Gentris Corporation is a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions. As pioneers in the field of pharmacogenomics, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market sooner. Gentris is developing diagnostic test kits and validated reference controls that will bring the promise of personalized medicine to physicians and patients, which will enhance patient management, improve patients' response to therapy and revolutionize medicine through pharmacogenomics. For additional information, please visit http://www.gentris.com.
Contact
919 Marketing
Jonathan Jordan
919-557-7890
www.gentris.com
Jonathan Jordan
919-557-7890
www.gentris.com
Contact
Categories